Clinical trial · Interventional
Study of Oral ENMD-2076 Administered to Patients With Ovarian Cancer
A Phase 2 Study of Oral ENMD-2076 Administered to Patients With Platinum Resistant Ovarian Cancer
NCT01104675CI-TRIAL-00015326completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine whether oral ENMD-2076 is effective in treatment of patients with platinum resistant ovarian, fallopian, or peritoneal cancer. Additional sites to be added.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Fallopian Cancer | Ovarian Neoplasm | PROBABILISTIC | 0.70 |
| Ovarian Cancer | Malignant Ovarian Neoplasm | CURATED_EXACT | 0.92 |
| Peritoneal Cancer | Malignant Peritoneal Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| ENMD-2076 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- ENMD-2076 treatment
- interventionNames
- Drug: ENMD-2076
Primary outcomes (1)
- measure
- Progression free survival rate
- timeFrame
- 6 months
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Have histologically documented diagnosis of ovarian, fallopian or peritoneal cancer that is platinum resistant. * Have a pre-study echocardiogram or multigated acquisition (MUGA) scan with an actual left ventricular ejection fraction of greater than or equal to the institution lower limit of normal * Greater than or equal to 18 years of age * Have clinically acceptable laboratory screening results * Have an ECOG performance status of 0 or 1 * Able to tolerate oral medications Exclusion Criteria: * Have uncontrolled hypertension (systolic blood pressure greater than 150mmHg or diastolic blood pressure greater than 100mmHg); require two or more antihypertensive medications to control hypertension (including ACE inhibitors, beta blockers, calcium channel blockers, or diuretics) * Have chronic atrial fibrillation or QTc interval corrected for heart rate of greater than 470 msec * Have active, acute, or chronic clinically significant infections or bleeding * Have persistent 2+ protein by urinalysis or a history of nephrotic syndrome
References
Publications (0)
Data not yet available
No reference posted for this study.